AU
UK
CA
US
IND
NZ
Last update at 2026-06-03T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
Thu 15 May 25, 11:01 AMWhat's Going On With Invivyd Stock On Monday?
Mon 21 Apr 25, 01:58 PMInvivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
Mon 21 Apr 25, 11:01 AMInvivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
Wed 26 Mar 25, 08:15 PMWhy Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025
Tue 04 Feb 25, 12:20 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -241.31700M | -226.79000M | - |
| Minority interest | - | - | - |
| Net income | -234.60300M | -234.28900M | - |
| Selling general administrative | 47.04M | 36.52M | - |
| Selling and marketing expenses | - | - | - |
| Gross profit | - | - | - |
| Reconciled depreciation | 0.46M | 0.00100M | - |
| Ebit | -248.03100M | -226.90800M | -43.20344M |
| Ebitda | -204.48500M | -211.90800M | - |
| Depreciation and amortization | 43.55M | 15.00M | - |
| Non operating income net other | 6.71M | - | - |
| Operating income | -248.03100M | -226.90800M | - |
| Other operating expenses | 226.26M | 219.41M | - |
| Interest expense | 43.08M | 15.00M | - |
| Tax provision | - | - | - |
| Interest income | - | - | - |
| Net interest income | - | - | - |
| Extraordinary items | - | - | - |
| Non recurring | 4.40M | - | - |
| Other items | - | - | - |
| Income tax expense | -6.71400M | 7.50M | - |
| Total revenue | 0.00000M | 0.00000M | - |
| Total operating expenses | 226.26M | 219.41M | - |
| Cost of revenue | - | - | - |
| Total other income expense net | 6.71M | 0.12M | - |
| Discontinued operations | - | - | - |
| Net income from continuing ops | -241.31700M | -226.79000M | - |
| Net income applicable to common shares | -241.31700M | -226.79000M | -111.97545M |
| Preferred stock and other adjustments | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 229.18M | 383.17M | 620.09M | 117.38M |
| Intangible assets | - | - | - | - |
| Earning assets | - | - | - | - |
| Other current assets | 23.31M | 4.93M | 25.29M | 0.14M |
| Total liab | 51.71M | 27.20M | 62.07M | 182.63M |
| Total stockholder equity | 177.47M | 355.97M | 558.02M | -65.24900M |
| Deferred long term liab | - | - | - | - |
| Other current liab | 40.90M | 21.95M | 56.28M | 4.92M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.00100M |
| Capital stock | 0.01M | 0.01M | 0.01M | 89.71M |
| Retained earnings | -732.06900M | -533.42600M | -292.10900M | -65.31900M |
| Other liab | - | 0.00100M | 0.01M | 0.01M |
| Good will | - | - | - | - |
| Other assets | - | 0.19M | 3.30M | - |
| Cash | 200.64M | 92.08M | 542.22M | 114.99M |
| Cash and equivalents | - | - | - | - |
| Total current liabilities | 50.29M | 25.03M | 62.06M | 13.07M |
| Current deferred revenue | - | - | - | - |
| Net debt | -198.47600M | -88.35200M | -542.22400M | -114.98800M |
| Short term debt | 1.44M | 1.56M | - | - |
| Short long term debt | - | - | - | - |
| Short long term debt total | 2.17M | 3.72M | - | - |
| Other stockholder equity | 680.36M | 506.49M | 850.12M | -89.63700M |
| Property plant equipment | - | 2.28M | 0.08M | - |
| Total current assets | 224.88M | 376.92M | 616.71M | 117.38M |
| Long term investments | - | - | - | - |
| Net tangible assets | - | 355.97M | 558.02M | -65.24900M |
| Short term investments | 0.00000M | 279.92M | 49.19M | - |
| Net receivables | 0.93M | 0.38M | 0.23M | - |
| Long term debt | - | - | - | - |
| Inventory | - | -0.37700M | - | - |
| Accounts payable | 7.95M | 1.52M | 5.78M | 8.15M |
| Total permanent equity | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - |
| Accumulated other comprehensive income | -0.01300M | -0.27200M | -0.00800M | - |
| Additional paid in capital | - | - | - | - |
| Common stock total equity | - | 0.01M | - | - |
| Preferred stock total equity | - | - | - | - |
| Retained earnings total equity | - | -533.42600M | - | - |
| Treasury stock | - | - | - | - |
| Accumulated amortization | - | - | - | - |
| Non currrent assets other | 0.17M | 0.19M | 3.30M | - |
| Deferred long term asset charges | - | - | - | - |
| Non current assets total | 4.30M | 6.25M | 3.38M | 0.00000M |
| Capital lease obligations | 2.17M | 3.72M | - | - |
| Long term debt total | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -228.96200M | -50.62700M | -50.62700M |
| Change to liabilities | -39.12800M | -2.37000M | 13.98M |
| Total cashflows from investing activities | -230.66700M | -50.71100M | -50.71100M |
| Net borrowings | - | - | - |
| Total cash from financing activities | 0.51M | 662.68M | 222.10M |
| Change to operating activities | -11.83000M | 25.16M | 4.33M |
| Net income | -241.31700M | -226.79000M | -111.97545M |
| Change in cash | -450.14800M | 427.24M | 197.12M |
| Begin period cash flow | 542.22M | 114.99M | - |
| End period cash flow | 92.08M | 542.22M | 114.99M |
| Total cash from operating activities | -219.98700M | -184.73600M | -24.97886M |
| Issuance of capital stock | 0.00000M | 666.07M | - |
| Depreciation | 0.46M | 0.00100M | 0.00100M |
| Other cashflows from investing activities | - | - | - |
| Dividends paid | - | - | - |
| Change to inventory | - | - | - |
| Change to account receivables | - | - | - |
| Sale purchase of stock | -0.00400M | 0.00000M | - |
| Other cashflows from financing activities | 0.27M | 331.78M | -3.38500M |
| Change to netincome | 39.02M | 19.26M | 68.69M |
| Capital expenditures | 1.71M | 0.08M | 0.08M |
| Change receivables | - | - | - |
| Cash flows other operating | 23.42M | - | - |
| Exchange rate changes | - | - | - |
| Cash and cash equivalents changes | -450.14800M | - | - |
| Change in working capital | -16.13000M | 22.79M | - |
| Stock based compensation | 21.65M | 17.76M | - |
| Other non cash items | 15.35M | 0.07M | - |
| Free cash flow | -221.69200M | -184.82000M | - |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| IVVD Invivyd Inc. |
-0.04 3.51% | 1.10 | - | - | - | 1.98 | -0.7447 | |
| NVO Novo Nordisk A/S |
-0.92 2.14% | 42.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.75 1.73% | 42.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.25 0.76% | 428.34 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
16.03 2.66% | 618.95 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
1601 Trapelo Road, Waltham, MA, United States, 02451
| Name | Title | Year Born |
|---|---|---|
| Mr. David Hering M.B.A. | CEO & Director | 1975 |
| Ms. Jill Andersen J.D. | Chief Legal Officer & Corp. Sec. | 1973 |
| Ms. Laura Walker Ph.D. | Co-Founder & Chief Scientific Officer | 1985 |
| Mr. Frederick W. Driscoll | Interim CFO, Principal Financial Officer & Principal Accounting Officer | 1951 |
| Dr. Rebecca Dabora Ph.D. | Chief Technology & Manufacturing Officer | 1959 |
| Kyra Rosow Faircloth | VP of Gov. Affairs, Advocacy & Corp. Communication | NA |
| Dr. Peter C. Schmidt M.D., M.Sc. | Chief Medical Officer | NA |
| Mr. David Hering M.B.A. | CEO & Director | 1976 |
| Ms. Jill Andersen J.D. | Chief Legal Officer & Corporate Secretary | 1973 |
| Mr. William E. Duke Jr., M.B.A. | Chief Financial Officer | 1972 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...